Skip to main content
  1. Right Decisions
  2. GGC - Clinical Guideline Platform
  3. Gynaecology
  4. Back
  5. Gynaecology guidelines
  6. E-Vetting Guidance (907)
Announcements and latest updates

Right Decision Service newsletter: September 2024

Welcome to the Right Decision Service (RDS) newsletter for September 2024.

1.Business case for permanent provision of the Right Decision Service from April 2025 onwards

This business case has now been endorsed by the HIS Board and will shortly be submitted to Scottish Government.

2. Management of RDS support tickets

To balance increasing demand with available capacity and financial resource, the RDS team and Tactuum are now working together to  implement closer management of support tickets. As a key part of this, we want to ensure clear, timely and consistent communication with yourselves as requesters.  

Editors will now start seeing new messages come through in response to support ticket requests which reflect this tightening up and improvement of our processes.

Key points to note are:

2.1 Issues confirmed by the RDS and Tactuum teams as meeting the critical/urgent and high priority criteria will continue to be prioritised and dealt with immediately.

Critical/urgent issues are defined as:

  1. The Service as a whole is not operational for multiple users. OR
  2. Multiple core functions of the Service are not operational for multiple users.

Example – RDS website outage.

Please remember to email ann.wales3@nhs.scot and his.decisionsupport@nhs.scot with any critical/urgent issues in addition to raising a support ticket.

High priority issues are defined as:

  1. A single core function of the Service is not operational for multiple users. OR:
  2. Multiple non-core functions of the Service are not operational for multiple users.

Example – Build to app not working.

2.2 Support requests that are outwith the warranty period of 12 weeks since the software was originally developed will not be automatically addressed by Tactuum. The RDS team will consider these requests for costed development work and will obtain estimate of effort and cost from Tactuum for priority issues.

2.3 Support tickets for technical issues that are not classified as bugs will not be automatically addressed by Tactuum. The definition of a bug is ‘a defect in the software that is at variance with documented user requirements.’  Issues that are not bugs will also be considered for costed development work.

The majority of issues currently in support tickets fall into category 2 or 3 above, or both.

2.4 Non-urgent requests that require a deployment (i.e a new release of RDS) will normally be factored into the next scheduled release (currently end of Nov 2024 and end of Feb 2025) unless by special agreement with the RDS team.

Please note that we plan to move in the new year to a new system whereby requests all come to an RDS support portal in the first instance and are triaged from there to Tactuum when appropriate.

We will be organising a webinar in a few weeks’ time to take you through the details of the current support processes and criteria.

3. Next scheduled deployment.

The next scheduled RDS deployment will take place at the end of November 2024.  We are reviewing all outstanding support tickets and feature requests along with estimates of effort and cost to determine which items will be included in this deployment.

We will update you on this in the next newsletter and in the planned webinar about support ticket processes.

4. Contingency arrangements for RDS

Many thanks to those of you who attended our recent webinar on the contingency arrangements being put in place to prevent future RDS outages as far as possible and minimise impact if they do occur.  Please contact ann.wales3@nhs.scot if you would like a copy of the slides from this session.

5. Transfer of CKP pathways to RDS

The NES clinical knowledge pathway (CKP) publisher is now retired and the majority of pathways supported by this tool have been transferred to the RDS. Examples include:

NHS Lothian musculoskeletal pathways

NHS Fife rehabilitation musculoskeletal pathways

NHS Tayside paediatric pathways

6. Other new RDS toolkits

Include:

Focus on frailty (from HIS Frailty improvement programme)

NHS GGC Money advice and support

If you would like to promote one of your new toolkits through this newsletter, please contact ann.wales3@nhs.scot

To go live imminently:

  • Focus on dementia
  • NHS Lothian infectious diseases toolkit
  • Dumfries and Galloway Adult Support and Protection procedures
  • SIGN guideline – Prevention and remission of type 2 diabetes

 

7. Evaluation projects

We have recently analysed the results of a survey of users of the Scottish Palliative Care Guidelines toolkit.  Key findings from 61 respondents include:

  • Most respondents (64%) are frequent users of the toolkit, using it either daily or weekly. A further 25% use it once or twice per month.
  • 5% of respondents use the toolkit to deliver direct patient care and 82% use it for learning
  • Impact on practice and decision-making was rated as very high, with 80% of respondents rating these at a 4-5 on a 5 point scale.
  • Impact on time saving was also high, with 74% of respondents rating it from 3-5.
  • 74% also reported that the toolkit improved their knowledge and skills, rating these at 4-5 on the Likert scale

Key strengths identified included:

  • The information is useful, succinct, and easy to understand (31%).
  • Coverage is comprehensive (15%)
  • All information is readily accessible in one place and users value the offline access via mobile app (15%)
  • Information is reliable, evidence-based and up to date (13%)

Users highlighted key areas for improvement in terms of navigation and search functionality. The survey was very valuable in enabling us to uncover the specific issues affecting the user experience. Many of these can be addressed through content management approaches. The issues identified with search results echo other user feedback, and we are costing improvements with a view to implementation in the next RDS deployment.

8.RDS High risk prescribing (polypharmacy) decision support embedded in Vision and EMIS primary care E H R systems

This decision support software, sponsored by Scottish Government Effective Prescribing and Therapeutics Division,  is now available for all primary care clinicians across NHS Tayside. Board-wide implementation is also planned for NHS Lothian, and NHS GGC, NHS Ayrshire and Arran and NHS Dumfries and Galloway have initial pilots in progress. The University of Dundee has been commissioned to evaluate impact of this decision support software on prescribing practice.

9. Video tutorials for RDS editors

Ten bite-size (5 mins or less) video tutorials for RDS editors are now available in the “Resources for providers of RDS tools” section of the RDS.  These cover core functionality including Save and preview, content page and media management, password management and much more.

10. Training sessions for new editors (also serve as refresher sessions for existing editors) will take place on the following dates:

  • Wednesday 23rd October 4-5 pm
  • Tuesday 29th October 11 am -12 pm

To book a place, please contact Olivia.graham@nhs.scot, providing your name, organisation, job role, and level of experience with RDS editing (none, a little, moderate, extensive.)

If you have any questions about the content of this newsletter, please contact his.decisionsupport@nhs.scot  

With kind regards

 

Right Decision Service team

Healthcare Improvement Scotland

 

 

 

E-Vetting Guidance (907)

Warning

Please report any inaccuracies or issues with this guideline using our online form

This guidance has been developed to assist the vetting process for GGC gynaecology referrals. The guidance aims to ensure there is appropriate and consistent access to gynaecology services in GGC.

General guidance

1. Downgrading of referrals from urgent to routine

All the following points must be completed:

  • GP must have examined patient, the examination must have been complete and normal
  • Outline reasons to the referrer for downgrading (e.g. normal smear, normal cervix, premenopausal with no risk factors so low risk for endometrial malignancy etc.)
  • Suggest interim treatment if appropriate
  • Advise GP to re-refer as urgent if symptoms persist or deteriorate

2. Suitability of referrals for a virtual appointment

  • GP has done a vaginal examination that is normal
  • Up to date with normal smear
  • Up to date BMI
  • No treatment or no failed treatment initiated by GP
  • If patient requires interpreter including BSL, consider suitability ( Attend Anywhere can facilitate remote interpreter)
  • Does not need USS or biopsy ( many patients will have been scanned prior to referral)
  • A virtual appointment can be offered even if an examination or scan is needed if it is felt that explanation and discussion virtually beforehand would significantly shorten the face-to face time.

3. Suitability for replying to referral with standardised advice

  • GP has examined patient and examination is normal
  • Normal smear where appropriate
  • No further investigation required before treatment/ management initiated
  • Standardised advice is available for HMB, PCOS, vulval itch, menopause/HRT, incontinence /prolapse, IMB/PCB

Vetting advice for specific conditions

  • PMB
    Has uterus/cervix- vet as USOC/URGENT- PMB/onestop North (clinic F)

    PMB- no uterus/cervix- GP has NOT examined or examination abnormal- vet as USOC/URGENT- general gynaecology

    PMB- no uterus/cervix- GP has examined and normal vault and vulva- Downgrade to ROUTINE, vet to general gynaecology and ask GP to check for haematuria

 

  • HMB 
    Women <40 can be vetted to a general clinic. Women ≥40 should be vetted to a one-stop clinic

    Women <45 with HMB with no risk factors for endometrial pathology / normal examination should be vetted as ROUTINE

    Women aged 40-44 with HMB AND persistent IMB or PCB, with no other risk factors for endometrial pathology should be vetted as ROUTINE

    Women aged 40-44 with HMB AND persistent IMB or PCB AND one or more additional risk factors for endometrial pathology should be vetted as URGENT

    Women ≥ 45 with no irregular bleeding, normal examination and no additional risk factors for endometrial pathology should be vetted as ROUTINE

    Women ≥45 with any additional risk factors for endometrial pathology OR persistent IMB / PCB OR treatment failure (continual use of hormonal treatment for 6 months) should be vetted as URGENT

 

  • IMB
    Women <40 with normal examination should be referred back to GP with advice to review hormonal contraception and exclude infection. If starting / changing hormonal contraception or treating infection is not successful, then vet as ROUTINE to general gynaecology.

    Women ≥ 40 with persistent IMB with normal examination, but who have risk factors for endometrial pathology (eg PCOS, BMI>40, current / past tamoxifen use) should be vetted as URGENT.

    Women ≥40 with no risk factors – vet as ROUTINE

 

  • PCB
    If appearance suspicious /consistent with cervical cancer vet as USOC to colposcopy.

    If abnormal cervical screening, vet to colposcopy as per usual protocol

    Women < 40 with normal smear / examination should be offered STI screen. Consider change of OCP / trial of Relactagel®. If ineffective, vet as ROUTINE to gynaecology or colposcopy as per local service provision.

    Women ≥40 – vet as URGENT 

 

  • PCOS
    Most referrals can be managed by sending standardised advice to GP- if an appointment is felt necessary this should be VIRTUAL unless there is significant menstrual disorder (e.g. requiring LNG-IUS etc)

 

  • CERVICAL POLYP
    Asymptomatic, normal smear- vet to ROUTINE general gynaecology appointment. If symptomatic (e.g. PCB/IMB), < 40 years vet as ROUTINE to general gynaecology, >40 years vet as ROUTINE to PMB/onestop North (clinic F)

 

  • VULVAL ITCH/DISCOMFORT
    If GP has examined and no focal abnormality (e.g. ulcer) and no treatment, send referral back to referrer with standardised vulval care advice.

    If examination by GP is abnormal or there has been treatment failure, vet to general gynaecology (vulva clinics are tertiary referral only). Grade depending on appearance of abnormality.

 

  • INCONTINENCE/PROLAPSE
    Current NICE guidance is for conservative management in the first instance- refer to SPHERE bladder and bowel service. OAB symptoms can be managed with medication (send GP standardised advice). Women with failed management or treatment should be vetted as routine to urogynaecology.

 

  • PELVIC PAIN/ QUERY ENDOMETRIOSIS
    If GP has examined and normal smear, vet as ROUTINE to virtual appointment

 

  • STERILISATION REQUEST
    Vet as routine to virtual appointment- send referral back to referrer if BMI >35 or no BMI recorded

 

  • MENOPAUSE/HRT
    Some referrals can be dealt with by sending standardised advice to GP. If appointment needed vet as routine to VIRTUAL appointment

 

  • ULTRASOUND
    Some referrals can be vetted directly to gynae USS ( e.g. asymptomatic simple cyst < 5cm, or radiology have suggested TVUSS) 

 

  • FINDING OF POSTMENOPAUSAL INCIDENTAL INCREASED ENDOMETRIAL THICKNESS/FLUID IN ENDOMETRIAL CAVITY
    In the absence of PMB vet as ROUTINE to PMB/onestop North (clinic F)

ADDENDUM December 2020

RE-GRADING OF USOC (URGENT SUSPICION OF CANCER) REFERRALS

  • It has been agreed that during COVID-19 pandemic Urgent Suspicion of Cancer (USOC) referrals can be re-prioritised at vetting to urgent or routine where a referral does not meet the Scottish Cancer Referral Guidelines
  • Scottish Cancer Referral Guidelines can be accessed at: http://www.cancerreferral.scot.nhs.uk/
  • An automated letter will be sent to Primary Care noting re-prioritisation. Thus ensuring clear communication back to GP whilst minimising impact on vetting clinician in dictating letter.
  • A 2 stage vetting process has been implemented in Trakcare:
    1. Select ‘downgrade of cancer’ in vetting outcomes, this will generate letter to GP; then
    2. Re-grade referral and assign appropriate vetting outcome

Editorial Information

Last reviewed: 01/02/2021

Next review date: 30/06/2024

Author(s): Claire Higgins.

Approved By: Gynaecology Clinical Governance Group

Document Id: 907